Clinical Trial Update: To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses [Phase 1]

View source ↗

Summary

Phase 1 study of AZD2820 in obesity assessing safety, tolerability, PK and PD was terminated; the study status is TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• AZD2820

Snippet

Sponsor: AstraZeneca | Conditions: Obesity | Phase 1 | Status: TERMINATED